FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.
What happened
FDA inspected American Behavioral Research Institute (ABRI) from April 17 to May 3, 2024, reviewing its role as sponsor of Protocol ABRI-002, a study of Relaxium® Sleep in people with sleep disorder. FDA found ABRI began and ran the study without submitting an Investigational New Drug application (IND, the FDA filing required before testing a drug in humans) or having one in effect, and that 40 human subjects were enrolled and received the investigational drug. FDA concluded Relaxium was used as a drug in this study because the protocol measured its effect on insomnia.
What FDA found
ABRI started and ran a clinical study of Relaxium Sleep in humans without submitting an IND to FDA and having it in effect first.
21 CFR 312.20(a), 312.20(b), 312.40(a)FDA treated Relaxium as a drug in this study because the protocol measured whether it reduced insomnia, which is use to treat a disease.
Section 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)]The study did not qualify for any IND exemption, because an exempt product must be lawfully marketed as a drug and Relaxium is marketed as a dietary supplement.
21 CFR 312.2ABRI's written response did not give enough detail of a corrective and preventive action plan for following IND rules if it runs another study.
What FDA wants
Within 15 business days of receiving the letter, ABRI must write to FDA describing the actions it has taken to prevent similar violations, or explain why it believes it complied, with supporting information. FDA said failure to address the matter adequately may lead to regulatory action.
Who should pay attention
- sponsors of small or investigator-run clinical studies
- dietary supplement companies that want to test their products in people
- IRBs and contract research organizations reviewing sleep or supplement studies
This is a summary. Read the original letter on fda.gov.